Please login to the form below

Not currently logged in
Email:
Password:

PRV

This page shows the latest PRV news and features for those working in and with pharma, biotech and healthcare.

Alexion uses priority review voucher for Soliris follow-up

Alexion uses priority review voucher for Soliris follow-up

Alexion is pulling out all the stops to get speedy approval for a follow-up to its rare blood disorder therapy Soliris, using a coveted priority review voucher (PRV) to accelerate ... Alexion is sitting on a pair of PRVs awarded for earlier approvals for

Latest news

  • Sanofi pays $245m for FDA priority review voucher Sanofi pays $245m for FDA priority review voucher

    Sanofi pays $245m for FDA priority review voucher. PRV reduces review time from ten to six months. ... The French pharma major is paying small US drugmaker Retrophin $245m for the priority review voucher (PRV), awarded as an incentive for carrying out

  • J&J files new resistant TB drug bedaquiline in US

    The PRV would allow J&J to request priority review for another of its marketing applications. ... J&J was the first company to make use of a PRV after being awarded one for the approval of its antimalarial treatment Coartem (artemether/lumefantrine) in

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy. ... Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv

  • Pharma deals in August 2015 Pharma deals in August 2015

    In 2012 the PRV programme was extended to include rare pediatric diseases and the emergence of trading in PRVs was noted in our last annual Deal Watch report. ... Keeping this trend, United Therapeutics has sold a PRV to AbbVie for a headline value of

  • Pharma deals in May 2015 Pharma deals in May 2015

    The paediatric PRV was issued when Cholbam was approved for the treatment of patients with peroxismal disorders. ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam [cholic acid] in bile acid disorders.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Introduced by the FDA in 2007, a PRV is an incentive for companies to invest in treatments for neglected tropical diseases. ... Selling PRVs is a relatively new area and so these two deals provide initial benchmarks, however it will be interesting to see

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics